Wei Chen - EUDA Health CEO Director
| EUDAW Stock | 0.09 0.01 5.26% |
Insider
Wei Chen is CEO Director of EUDA Health Holdings
| Age | 39 |
| Address | 1 Pemimpin Drive #12-06, Singapore, Singapore, 576151 |
| Phone | 65 6268 6821 |
| Web | https://euda.com |
Wei Chen Latest Insider Activity
Tracking and analyzing the buying and selling activities of Wei Chen against EUDA Health stock is an integral part of due diligence when investing in EUDA Health. Wei Chen insider activity provides valuable insight into whether EUDA Health is net buyers or sellers over its current business cycle. Note, EUDA Health insiders must abide by specific rules, including filing SEC forms every time they buy or sell EUDA Health'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Wei Chen over a year ago Acquisition or disposition of EUDA Health securities by Wei Chen | ||
Wei Chen over a year ago EUDA Health exotic insider transaction detected |
EUDA Health Management Efficiency
The company has return on total asset (ROA) of (0.863) % which means that it has lost $0.863 on every $100 spent on assets. This is way below average. EUDA Health's management efficiency ratios could be used to measure how well EUDA Health manages its routine affairs as well as how well it operates its assets and liabilities. At this time, EUDA Health's Return On Capital Employed is fairly stable compared to the past year. Return On Equity is likely to climb to 1.91 in 2024, despite the fact that Return On Tangible Assets are likely to grow to (7.28). At this time, EUDA Health's Intangible Assets are fairly stable compared to the past year. Non Currrent Assets Other is likely to climb to about 399.1 K in 2024, whereas Non Current Assets Total are likely to drop slightly above 557.7 K in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Lina Gugucheva | NewAmsterdam Pharma | 37 | |
| Joseph McClellan | Alvotech Warrant | 50 | |
| Steven Sobak | EUDA Health Holdings | 78 | |
| Anil Okay | Alvotech Warrant | 38 | |
| Ming Li | Alvotech Warrant | 47 | |
| Sean Gaskell | Alvotech Warrant | 42 | |
| Annie Neild | NewAmsterdam Pharma | N/A | |
| Louise Kooij | NewAmsterdam Pharma | 48 | |
| Raphi Levy | Alpha Tau Medical | 39 | |
| Ronen Segal | Alpha Tau Medical | 51 | |
| Suketu Desai | Scilex Holding | 58 | |
| FESC MD | NewAmsterdam Pharma | 68 | |
| Robert Wessman | Alvotech Warrant | 54 | |
| Pr Kelson | Alpha Tau Medical | 84 | |
| Amnon Gat | Alpha Tau Medical | 49 | |
| Reem Malki | Alvotech Warrant | 53 | |
| Robert MD | Alpha Tau Medical | 45 | |
| Uzi Sofer | Alpha Tau Medical | 54 | |
| Steven JD | Scilex Holding | N/A | |
| Mark Levick | Alvotech Warrant | 60 | |
| Daniel Tan | EUDA Health Holdings | 43 | |
Management Performance
| Return On Asset | -0.86 |
EUDA Health Holdings Leadership Team
Elected by the shareholders, the EUDA Health's board of directors comprises two types of representatives: EUDA Health inside directors who are chosen from within the company, and outside directors, selected externally and held independent of EUDA. The board's role is to monitor EUDA Health's management team and ensure that shareholders' interests are well served. EUDA Health's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, EUDA Health's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Wei Chen, CEO Director | ||
| Steven Sobak, Chief Officer | ||
| Daniel Tan, Chief Officer | ||
| Alfred Lim, Executive Director | ||
| Jenifer Goh, President Operations | ||
| Whye Tay, Interim CFO | ||
| Yew CPA, Chief Officer |
EUDA Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is EUDA Health a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.86 | ||||
| Operating Margin | (0.83) % | ||||
| Number Of Shares Shorted | 5.68 K | ||||
| Revenue | 3.71 M | ||||
| EBITDA | (8.3 M) | ||||
| Net Income | (8.44 M) | ||||
| Total Debt | 3.37 M | ||||
| Book Value Per Share | (0.17) X | ||||
| Cash Flow From Operations | (2.92 M) | ||||
| Number Of Employees | 106 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for EUDA Stock Analysis
When running EUDA Health's price analysis, check to measure EUDA Health's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy EUDA Health is operating at the current time. Most of EUDA Health's value examination focuses on studying past and present price action to predict the probability of EUDA Health's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move EUDA Health's price. Additionally, you may evaluate how the addition of EUDA Health to your portfolios can decrease your overall portfolio volatility.